product name 6-Thio-dG
Description: 6-thio-dG is a nucleoside analog and a telomerase-mediated telomere disrupting compound. It is used as an anti-cancer agent. Cancer cells were very sensitive to 6-thio-dG with observed IC50 values ranging from 0.7-2.9 μM, depending on cell types. 6-Thio-dG induces telomere dysfunction and results in progressive telomere shortening in telomerase-positive human cancer cells and hTERT-expressing human fibroblasts. In tested cancer cells, 6-thio-dG inhibits cell viability with IC50 values between 0.7 and 2.9 μM.
References: Cancer Discov. 2015 Jan;5(1):82-95.
283.31
Formula
C10H13N5O3S
CAS No.
789-61-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 56 mg/mL (197.7 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19411611
| In Vitro |
In vitro activity: 6-Thio-dG induces telomere dysfunction and results in progressive telomere shortening in telomerase-positive human cancer cells and hTERT-expressing human fibroblasts. In tested cancer cells, 6-thio-dG inhibits cell viability with IC50 values between 0.7 and 2.9 μM. Kinase Assay: Cell Assay: Cells (HCT11, A549, H2882, HCC2429, HCC827, HCC15, H2087, HCC4017, HCC515, H2009, BJ and HCEC1 cells) are plated in growth media in 96-well plates. Cells are incubated for 1 week and treated with varying concentrations of 6-thio-dG and 6-thioguanine or DMSO every 3 days. The 96-well plates are analyzed according the manufacturer’s directions for the CellTiterGlo luminescent cell viability assay to obtain IC50 values. The IC50 is defined as the concentration of drug at which 50% of the cells are inhibited by the drug. Sigmoidal dose–response curves are used to calculate IC50 values. All samples are analyzed in triplicate, and SDs are from two independent experiments. |
|---|---|
| In Vivo | In mice bearing A549 lung cancer xenografts, 6-Thio-dG (2 mg/kg, i.p.) decreases the tumorigenicity of A549 Cells by inducing telomere dysfunction. |
| Animal model | Mice bearing A549 lung cancer xenografts |
| Formulation & Dosage | Dissolved in 5% DMSO solution; 2 mg/kg; i.p. injection |
| References | Cancer Discov. 2015 Jan;5(1):82-95. |
